Stryker Corporation $SYK Shares Sold by Act Two Investors LLC

Act Two Investors LLC trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 15.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,053 shares of the medical technology company’s stock after selling 2,128 shares during the period. Stryker accounts for approximately 0.7% of Act Two Investors LLC’s holdings, making the stock its 23rd largest holding. Act Two Investors LLC’s holdings in Stryker were worth $4,236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in SYK. Godfrey Financial Associates Inc. purchased a new stake in Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC purchased a new stake in Stryker in the 3rd quarter valued at $27,000. CGC Financial Services LLC purchased a new stake in Stryker in the 4th quarter valued at $29,000. Strive Asset Management LLC purchased a new stake in Stryker in the 3rd quarter valued at $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Stryker in the 3rd quarter valued at $34,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

SYK opened at $305.73 on Friday. The stock’s 50-day moving average price is $321.82 and its 200 day moving average price is $348.15. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market cap of $117.21 billion, a price-to-earnings ratio of 35.39, a PEG ratio of 1.92 and a beta of 0.80.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the company posted $2.84 EPS. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Ratings Changes

Several analysts have issued reports on SYK shares. Jefferies Financial Group restated a “buy” rating and issued a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. decreased their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Weiss Ratings lowered Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $395.48.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last quarter. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.